TSVT
The FDA sets March 15 as the date of its advisory committee meeting on an application from Bristol Myers Squibb and 2seventy bio seeking approval of the earlier use of their Abecma gene therapy in the treatment course for people with the blood cancer multiple myeloma.
Technically we formed Head&Shoulder Patterns! Strong level at 6.00,if we brake it we can see a huge move.
FDA approval plus Head&Sholders Pattern should be a huge potential!